UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease
UCB has formed a global co-development and co-commercialization agreement with Novartis for UCB0599, a small molecule alpha-synuclein misfolding inhibitor currently in Phase 2 development, and UCB7853, an anti-alpha-synuclein antibody pending Phase 1 completion. UCB will receive an upfront payment of US$150 million, with potential total payments nearing US$1.5 billion linked to regulatory and sales milestones. UCB will handle European and Japanese commercialization while Novartis will manage operations in the US and other regions. This agreement does not affect UCB's 2021 financial guidance.
- UCB receives an upfront payment of US$150 million.
- Potential total payments could reach US$1.5 billion upon attaining specific milestones.
- Partnership enhances capabilities in developing treatments for Parkinson's disease.
- None.
BRUSSELS, Dec. 2, 2021 /PRNewswire/ -- UCB today announced that it has entered into a global co-development and co-commercialization agreement with Novartis covering UCB0599, a potential first in class, small molecule, alpha-synuclein misfolding inhibitor currently in Phase 2 clinical development, and upon completion of the ongoing Phase 1 program, an opt-in to co-develop UCB7853, an anti-alpha-synuclein antibody, both in Parkinson's Disease (PD).
"This partnership has the potential to be transformational for people living with Parkinson's disease, as it will combine UCB's expertise as a leader in the field of neurodegenerative disease with Novartis' global capabilities and deep experience developing transformative, disease modifying treatments for a range of neurological conditions," said Dhaval Patel, Executive Vice President and Chief Scientific Officer at UCB. "It is a great example of our approach to research and development in neurodegeneration, building external networks and partnerships to access additional capabilities and knowledge, that help to accelerate the development of our medicines."
Charl van Zyl, Executive Vice President, Neurology & Head of Europe/International Markets commented: "It is our long-term ambition to transform the Parkinson's treatment landscape from the management of symptoms, to treatments that can slow or stop the progression of disease. By sharing resources and working together we think we can best optimize our chances of success and realize our Parkinson's ambitions."
Under the terms of the agreement, the parties will co-develop and co-fund the further global development of UCB0599. Novartis also have the right to "opt-in" to engage in global co-development of UCB7853 upon completion of a Phase 1 study currently being run by UCB. Further clinical development would then also be jointly funded and managed.
UCB will receive an upfront payment of US
This agreement does not impact UCB's 2021 financial guidance.
About UCB0599 and UCB7853
UCB0599 was in-licensed by UCB from Neuropore Therapies Inc. It is an orally administered, brain penetrant, small molecule inhibitor of alpha-synuclein misfolding under clinical investigation for the potential to slow the progression on Parkinson's. UCB7853 is an anti-alpha-synuclein monoclonal antibody under investigation for the potential treatment of people living with Parkinson's.
The most prominent neuropathological hallmark of Parkinson's is the abnormal accumulation and misfolding of the alpha-synuclein protein. This misfolding is thought to be a primary step in the pathological cascade that results in the progression of Parkinson's disease pathobiology culminating in the loss of neurons.
Through action on this early step in Parkinson's pathology, UCB0599 may have the potential to slow the progression of the disease and related clinical symptoms. A complementary approach may be achieved by targeting the extracellular spread of pathological species of alpha-synuclein with antibody therapies such as UCB7853. Collectively, UCB0599 and UCB7853 represent a unique opportunity to target a key pathobiology in Parkinson's and offer the potential to bring transformative treatments to patients.
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,300 people in approximately 40 countries, UCB generated revenue of
View original content:https://www.prnewswire.com/news-releases/ucb-announces-global-partnership-to-bring-disease-modifying-therapies-to-people-living-with-parkinsons-disease-301435734.html
SOURCE UCB
FAQ
What is the partnership between UCB and Novartis about?
What payments will UCB receive from Novartis?
What is UCB0599?
Is UCB7853 also in development?
How will commercialization responsibilities be split?
Does this agreement impact UCB's 2021 financial guidance?
